7. NCCN Guidelines CLL/SLL Version 1.2024 8. Miao Y, Sha Y, Xia Y, et al. Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 ab...
12. NCCN Guidelines. Version 2.2022. 13. Fischer K, et al. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ...
A.2; Paik, J.2; Shadman, M.11,12. P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL. HemaSphere
CALQUENCE® (acalabrutinib) is a BTK inhibitor indicated for the treatment of adult patients with R/R Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
A.2; Paik, J.2; Shadman, M.11,12. P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL. HemaSphere 6():p 560-561, June 2022. | DOI: 10.1097/01.HS9.0000845532.14560...
The median treatment-free survival (TFS) and overall survival (OS) was 16 months (4-24 months) and 180 months (145-215 months), respectively. ② The median TFS for low ( n=60), intermediate ( n=50), high ( n=45) and very high risk group ( n=60) according to the CLL-IPI ...
2.Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. 3.Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff’s Clinical Oncology. 6t...
All patients stopped the treatment after M24. The primary endpoint was the CR rate (IWCLL guidelines) with BM MRD 0.01% at M12 achieving a BM MRD < 0.01% at M24, proportion of patients in CR with BM MRD < 0.01% at M12 stopping treatment at M18 and overall survival (OS), progression-...
6 Accordingly, current guidelines stratify treatment based on presence of this genetic aberration. First-line therapy for patients with or without del(17p)/TP53 consists of acalabrutinib (Calquence; AstraZeneca) with or without obinutuzumab (Gazyva; Genentech), venetoclax (Venclexta; AbbVie and ...
[9] Annals of Oncology, Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, January 6, 2020.[10] Cerhan, J.R. and T.M. Habermann, Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma, 2021.[11] Smith, A., et al., Lymphoma incidence, ...